Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HCKJ-HN01 in moderate to severe dry eye disease
CTR20261620Phase 2Active
- Sponsor
- Fuzhou Haoji Pharmaceutical Technology Development
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HCKJ-HN01 in dry eye syndrome (DED), sponsored by Fuzhou Haoji Pharmaceutical Technology Development. Started Apr 2026; status: active.
02
Drugs
HCKJ-HN01
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20261620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261620.